Rumblings that psychedelic treatments would soon be ready for prime time gained credence aplenty, and shares of Ataibeckley ...

New research has teased out specific aspects of how Epstein-Barr virus (EBV) sparks the immune response that leads on to the development of multiple sclerosis (MS), opening the way to the rational ...

For the second time in two months, Celcuity Inc. failed to generate investor excitement despite disclosing positive news, ...

Newronika SpA received CE mark certification for its latest adaptive deep brain stimulation (aDBS) system, which includes the ...

The prophylaxis of bleeding disorders usually requires frequent intravenous infusions that result in excessive treatment burden and residual bleeding risk. TGM-148 is a siRNA developed by Tangram ...

The Oxford Vaccine Group has delivered on its promise, and after starting work in mid-May has completed preclinical testing and is ready to begin a phase I trial of a vaccine against the Bundibugyo ...

Despite multiple analgesics on the market, current therapeutics often fail at achieving complete pain relief and are usually ...

Another day, another two multibillion-dollar deals with Asian companies, this time involving Dizal Pharmaceutical Co. Ltd.

Clinical updates for biopharma and med tech, including data readouts and publications: AB Science, Alkermes, Ani, CEPI, Eisai, GSK, Hemab, Immutep, Incyte, Ipsen, Lighthouse, Longeveron, Novo Nordisk, ...

South Korea is moving ahead with its biggest reform of drug review and pricing in more than a decade, reflecting a wider ...

For decades, treatment options for osteoarthritis have followed a familiar path: As cartilage deteriorates and pain worsens, ...

Astrazeneca plc has added a dual PDE3/4 inhibitor candidate to its chronic obstructive pulmonary disease (COPD) portfolio via ...